MedTrace Logo

Study to Evaluate VORTX Rx (Theresa)

NCT03741088 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2021-04-20

Study results available
· View outcomes & findings →

Summary

Multi-center, Open-labeled, Non-randomized Study to Evaluate the Acute Technical Performance and Safety Profile of the VORTX Rx® for Ablation of Primary and Metastatic Liver Tumors

Conditions

  • Carcinoma, Hepatocellular
  • Liver Metastases

Interventions

DEVICE

VORTX Rx treatment

Cavitation-based cellular destruction using focused ultrasound

Sponsors & Collaborators

  • HistoSonics, Inc.

    lead INDUSTRY

Principal Investigators

  • Joan Vidal Jove, MD · Mutua Terrassa , Barcelona, Spain

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-21
Primary Completion
2019-05-15
Completion
2019-07-17
FDA Device
Yes

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03741088 on ClinicalTrials.gov